8.47

1.40% -0.12

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is currently priced at $8.47, with a 24-hour trading volume of 2.16M. It has seen a -1.40% decreased in the last 24 hours and a -8.63% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $8.50 pivot point. If it approaches the $8.30 support level, significant changes may occur.

Previous Close:

$8.59

Open:

$8.59

24h Volume:

2.16M

Market Cap:

$973.81M

Revenue:

$59.61M

Net Income/Loss:

$-262.14M

P/E Ratio:

-1.5289

EPS:

-5.54

Net Cash Flow:

$-247.49M

1W Performance:

-6.92%

1M Performance:

-8.63%

6M Performance:

+257.38%

1Y Performance:

-39.06%

1D Range:

$8.36

$8.85

52W Range:

$1.76

$15.21

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

805 418 5006

Address

2945 Townsgate Road, Suite 110, Westlake Village, CA

Employee

Twitter

@ArcutisBio

Next Earnings Date

2024-05-07

Latest SEC Filings

ARQT's Discussions on Twitter

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research

Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data

Arcutis Biotherapeutics Inc (ARQT) Revenue 2024

ARQT reported a revenue (TTM) of $59.61 million for the quarter ending December 31, 2023.

Arcutis Biotherapeutics Inc (ARQT) Net Income 2024

ARQT net income (TTM) was -$262.14 million for the quarter ending December 31, 2023, a +15.83% increase year-over-year.

Arcutis Biotherapeutics Inc (ARQT) Cash Flow 2024

ARQT recorded a free cash flow (TTM) of -$247.49 million for the quarter ending December 31, 2023, a +11.93% increase year-over-year.

Arcutis Biotherapeutics Inc (ARQT) Earnings per Share 2024

ARQT earnings per share (TTM) was -$3.92 for the quarter ending December 31, 2023, a +30.62% growth year-over-year.

Arcutis Biotherapeutics Inc Stock (ARQT) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Watanabe Todd Franklin	See Remarks	Mar 04 '24	Sale	11.12	14,903	165,739	874,533
Burnett Patrick	See Remarks	Mar 04 '24	Sale	11.12	4,782	53,182	269,300
Matsuda Masaru	See Remark	Mar 04 '24	Sale	11.12	3,760	41,816	190,424
Moore Matthew Richard	SVP and Chief Business Officer	Mar 04 '24	Sale	11.12	3,468	38,568	146,020
Watanabe Todd Franklin	See Remarks	Feb 28 '24	Sale	10.60	2,465	26,129	889,436
Burnett Patrick	See Remarks	Jan 02 '24	Sale	3.54	1,325	4,692	57,032
Watanabe Todd Franklin	See Remarks	Dec 01 '23	Option Exercise	1.68	59,525	100,038	513,682
Matsuda Masaru	See Remark	Nov 21 '23	Sale	1.98	1,850	3,661	46,634
Frazier Life Sciences VIII, L.	10% Owner	Oct 24 '23	Buy	2.50	80,000	200,000	8,764,232
Burnett Patrick	See Remarks	Aug 21 '23	Sale	7.04	1,605	11,302	58,357

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.